Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
What adjuvant therapy, if any, would you offer for a young fit patient with stage IB lung adenocarcinoma harboring an EGFR A763_Y764insFQEA who received no prior therapy?
Related Questions
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Will you offer lurbinectedin with atezolizumab for patients with ES-SCLC during maintenance if they had brain metastases at baseline?
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
Would a patient with a resected NSCLC mass under 3 cm, without lymph node involvement or distant metastases, but with visceral invasion identified on pathology, benefit from adjuvant therapy?
Would you provide vitamin B12 supplementation to a patient on pemetrexed therapy if their B12 levels are normal or high?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
How do you determine your next line of therapy In ALK+ metastatic NSCLC patients who have widespread progression on first-line lorlatinib?
How do you approach duration of immunotherapy in patients with metastatic NSCLC?
Is concurrent immuno-radiation therapy a viable treatment option for patients with unresectable, non-metastatic, locally advanced lung cancer, who have high PD-L1 expression and no oncogenic mutations?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
